Navigation Links
Cyberonics Reports Strong Revenue Growth and Profitability in Fiscal 2008 Fourth Quarter
Date:6/11/2008

Epilepsy Growth of 14%

Fiscal 2009 Revenue Guidance

HOUSTON, June 11 /PRNewswire-FirstCall/ -- Cyberonics, Inc. (Nasdaq: CYBX) today announced results for the fourth quarter, and fiscal year, ended April 25, 2008.

Key quarterly highlights

Key results for the fourth quarter of fiscal 2008 compared to the fourth quarter of fiscal 2007 included:

-- Net sales of $33.9 million, an 8% increase from $31.4 million.

-- Net earnings of $2.9 million, including $1.3 million in insurance

recoveries and $0.4 million in state tax credits, compared with a net

loss of $10.8 million.

-- Earnings per diluted share of $0.11 cents, including $0.07 in credits

from insurance recoveries and state tax credits, compared with a loss

of $0.42 cents per share.

-- Unit sales attributable to the epilepsy indication increased globally

by an estimated 18%, with US unit sales increasing by an estimated 20%.

Net sales

Net sales for fiscal 2008 were $121.2 million, compared to $131.0 million in fiscal 2007. Net product sales in fiscal 2008 attributable to the epilepsy indication were $115.3 million, an increase of $13.9 million, or 14% over fiscal 2007, while sales attributable to the depression indication declined by $24.1 million to $5.4 million from $29.5 million in fiscal 2007.

U.S. net product sales in fiscal 2008 declined to $94.4 million, compared with $111.1 million in fiscal 2007, due to the continued reduction in the number of VNS Therapy(TM) Systems attributable to treatment-resistant depression ("TRD"), following both the preliminary and final non-coverage determinations by the Centers for Medicare and Medicaid Services in February 2007 and May 2007, respectively; however, net sales attributable to the epilepsy indication increased by approximately 10% over the prior year.

International net sales increased by 3
'/>"/>

SOURCE Cyberonics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
2. YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING
3. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
4. Cord Blood America Reports CorCell, Its Major Acquisition in 2006, Turns Profitable
5. Bioheart, Inc. Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements
6. Rosetta Genomics Reports First Quarter 2008 Financial Results
7. Genetic Engineering and Biotechnology News (GEN) Reports on Mass Spec in Drug Discovery
8. Advance Nanotech Reports First Quarter 2008 Financial Results
9. Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results
10. Senetek PLC Reports First Quarter 2008 Financial Results
11. New Study Reports That Ablative Therapy With HALO360 Device Effectively Treats Highest-Risk Category of Barretts Esophagus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... 2015 , ... Proove Biosciences, a commercial and research ... genetics and hypertension at the International Academy of Cardiology Annual Scientific ... The event, which boasts an extensive overview of the latest research developments in ...
(Date:8/26/2015)... ... August 26, 2015 , ... Lee Biosolutions, a global biotech ... manufacture of highly valued cardiac markers used in early detection of heart disease ... chemistry has led to the development and commercialization of important cardiac biomarkers used ...
(Date:8/26/2015)... August 26, 2015 Israel Proves Its Place ... 1 st place  Wayerz comes in 5 th ... Israel by venture capital fund JVP, with Chinese consulting ... China , Israel , ... Impressive achievement for the Israeli representatives in the final ...
(Date:8/26/2015)... (PRWEB) , ... August 26, 2015 , ... PRC ... to develop new business relationships with local sponsors in southern California. The Clinical Trial ... their drug development processes and regulatory pathways., , Stem ...
Breaking Biology Technology:Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3
... Rapid Production, Increased Bioavailability, MOUNTAIN VIEW, Calif., ... are either incurable or difficult to treat allures ... prized, due to their,therapeutic potential, stem cell therapies ... Stem cell research progresses at a fast pace; ...
... Inc. (Nasdaq: CEPH ) and Eurand NV ... Paragraph IV Certification Notice Letter on October 20, ... to the U.S.,Food and Drug Administration (FDA) by ... a generic version of the 15 mg and,30 ...
... 71% of Evaluable Patients in the Trial,s First Stage ... Achieved Objective Tumor Responses- ... Second Stage-, TUSTIN, Calif., Oct. 21 Peregrine,Pharmaceuticals, Inc. (Nasdaq: ... cancer and serious viral,infections, today announced that updated preliminary data from ...
Cached Biology Technology:Innovation and Strong Therapeutic Potential Seen in Adult Stem Cells, According to Frost & Sullivan 2Innovation and Strong Therapeutic Potential Seen in Adult Stem Cells, According to Frost & Sullivan 3Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules 2Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules 3Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules 4Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer 2Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer 3Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer 4
(Date:8/12/2015)... , Aug. 12, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced that four of its ... solution, have officially been named FIDO Certified™ by ... of the certification, Synaptics, Natural ID™ fingerprint solutions ... Authentication Framework (UAF) standard and are interoperable among ...
(Date:8/6/2015)... Germany , August 6, 2015 /PRNewswire/ ... SensoMotoric Instruments (SMI) shows the world,s first ... based on Epson,s Moverio BT-200 see-through head mounted display ... new solution, unprecedented quality and efficiency is brought to ... displays. For the first time, professionals and researchers can ...
(Date:8/4/2015)... Aug. 04, 2015 ... has announced the addition of the ... and Service), Sub-Segment (Computer Forensics, Network Forensics, ... Types, Service, Vertical and Region - Global ... offering. By Component (Hardware, Software, ...
Breaking Biology News(10 mins):Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... a novel study, a University of Oklahoma researcher and collaborators ... test the toxicity of water or sediment was resistant to ... is the first to demonstrate that the indicator species may ... entirely unreliable source of information about ecosystem health. ...
... and forest disturbances may have a silver lining for ... a 10-year study that monitored 112 bears in Alberta,s ... and his colleagues found that warmer temperatures and easier ... grizzlies to build more body fat, known to increase ...
... scanners that give scientists a direct line of sight ... Fraser University researchers will use to help Ballard Power ... of these fuel cells in vehicles can substantially reduce ... Nano X-ray Computed Tomography (NXCT) tools will become part ...
Cached Biology News:OU research team finds a common bioindicator resistant to insecticides 2Climate change has silver lining for grizzlies 2Scientists to gain from view inside of fuel cells 2
... Tissue Arrays contain 60 rabbit tissue samples arrayed ... 4 unstained slides and 1 hematoxylin and eosin ... contains 15 different tissues from 4 rabbit organisms, ... slide. Each tissue sample (or core) is 1.5 ...
... offers custom peptide synthesis with a wide variety ... fit your research needs. Purity: ... 2mg-1g Sequence Length: Up ... Fluorescein, N-acetylation, C-amidation, phosphorylation, D-amino acids, MAPs, KLH/BSA ...
... Antigen sequence: H-Ala-Cys-Asp-Thr-Ala-Thr-Cys-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH 2 ... our corresponding peptide and ... 5 I-labelled peptide, ... (H-1470) and ([ 1 ...
... enables you to identify over 150 ... distinguish protein isoforms, protein subsets, and ... visualize peptide-protein associations and relationships easily. ... identification and relative protein expression analysis ...
Biology Products: